Verified Supplement Data Primary-sourced

Does Saffron Help Depression? The Honest Evidence

By Erin Rose · Updated · Methodology

Saffron has unusually real evidence for a supplement — and unusually important caveats. Across roughly 12–23 small trials and several meta-analyses, 30 mg/day of standardized saffron beat placebo for mild-to-moderate depressive symptoms, and small head-to-head trials found it comparable to fluoxetine and imipramine. But the trials are small, short (6–8 weeks), almost all from one country, some are conflicted, and the benefit shrinks on certain rating scales. It's a reasonable, low-risk option to discuss for mild low mood — not a replacement for care.

What the evidence actually shows

The meta-analyses are consistently positive versus placebo, with large effect sizes:

  • vs placebo: Tóth 2019 pooled 9 trials, Hedges' g ≈ 0.89 (large) (Tóth 2019); Marx 2019 pooled depression g ≈ 0.99 and anxiety g ≈ 0.95 across 23 studies (Marx 2019); Dai 2020 found saffron superior to placebo and comparable to antidepressants (Dai 2020).
  • vs antidepressants (small pilots): saffron 30 mg matched fluoxetine 20 mg (Noorbala 2005) and imipramine 100 mg, with fewer anticholinergic side effects than the tricyclic (Akhondzadeh 2004).
  • As an add-on: affron 28 mg/day added to an existing antidepressant improved clinician-rated MADRS (−41% vs −21% placebo) (Lopresti 2019).

The caveats that keep this honest

  • "Non-inferior to SSRIs" is fragile. Tóth's saffron-vs-antidepressant comparison had a confidence interval that just touched zero — suggestive, not a definitive equivalence.
  • The result depends on the ruler. Two meta-analyses found saffron significant on the Beck inventory but not on the Hamilton scale (Musazadeh 2022, Ghaderi 2020) — a real signal of fragility. Musazadeh's own conclusion: saffron "cannot be considered as a single therapeutic approach to treat depression."
  • In one add-on trial, self-rated mood didn't move. Lopresti 2019 found the benefit on clinician-rated MADRS but no difference on self-rated MADRS-S (−27% vs −26%).
  • Conflicts of interest. The Hausenblas 2013 meta-analysis authors disclosed being paid advisors to a saffron-supplement company (Hausenblas 2013), and most affron trials are funded by Pharmactive, affron's manufacturer, which also supplies the study product (and in at least one trial helped shape the study design, though analyses were run independently) — common in this field, but worth knowing when weighing the evidence.
  • Publication bias + one region. Marx 2019 explicitly flagged evidence of publication bias and a near-total concentration of trials in Iran.
  • Untested where it matters most. No trial has studied severe depression, suicidality, or long-term (>12 week) use.

The honest bottom line Saffron is one of the better-evidenced natural options for mild low mood, and small trials put it in the same ballpark as low-dose antidepressants over 6–8 weeks. But "works like Prozac" overstates a small, short, single-region, partly-conflicted evidence base. Treat it as a reasonable, low-risk thing to try or discuss for mild symptoms — an add-on or alternative to explore with a clinician, not a replacement for one.

If you want to try it

  • Dose: 30 mg/day of a standardized extract (15 mg twice daily), 6–8 weeks — see the dosage guide.
  • Buy a verifiable one (disclosed standardization), because saffron is heavily adulterated — see is your saffron real?
  • Loop in your doctor if you take any psychiatric medication, and never stop a prescribed antidepressant to switch to saffron.
  • Not in pregnancy. If you're pregnant or breastfeeding, skip supplemental saffron (high doses can stimulate the uterus) and ask your doctor about safer options for perinatal mood.

Frequently asked questions

Does saffron actually help with depression?

For mild-to-moderate symptoms, small trials and meta-analyses found 30 mg/day beat placebo (large effect) and matched fluoxetine/imipramine in pilots. But trials are small, short, mostly from one country, and some conflicted; untested in severe depression. Promising, not a proven treatment.

Is saffron as effective as antidepressants?

"Non-inferior" in one meta-analysis, but the margin nearly touched zero and the benefit vanished on the Hamilton scale in two others. The head-to-head trials are small and short — not a basis for replacing a prescribed medication.

Can I take saffron with my antidepressant?

Some add-on trials did this without serotonin syndrome, but saffron has serotonergic activity — clear it with your prescriber first, and never stop or adjust a prescribed antidepressant on your own to add it.

Related

Sources

  1. Tóth B, et al. "The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis." Planta Med. 2019. PMID: 30036891
  2. Marx W, et al. "Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis." Nutr Rev. 2019. PMID: 31135916
  3. Dai L, et al. "Safety and Efficacy of Saffron for Treating Mild to Moderate Depression: A Meta-analysis." J Nerv Ment Dis. 2020. PMID: 32221179
  4. Musazadeh V, et al. "Saffron, as an adjunct therapy, contributes to relieve depression symptoms: An umbrella meta-analysis." Pharmacol Res. 2022. PMID: 34757208
  5. Ghaderi A, et al. "The effects of saffron on mental health parameters and CRP: a meta-analysis." Complement Ther Med. 2020. PMID: 31987241
  6. Noorbala AA, et al. "Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine." J Ethnopharmacol. 2005. PMID: 15707766
  7. Akhondzadeh S, et al. "Comparison of Crocus sativus L. and imipramine." BMC Complement Altern Med. 2004. PMID: 15341662
  8. Lopresti AL, et al. "Efficacy of a standardised saffron extract (affron) as an add-on to antidepressant medication." J Psychopharmacol. 2019. PMID: 31475623
  9. Hausenblas HA, et al. "Saffron and major depressive disorder: a meta-analysis of RCTs." J Integr Med. 2013. PMID: 24299602 (authors disclosed as advisors to a saffron-supplement company).